Skip to main content

Table 7 mRNA expression of the 49 dysregulated genes in aneuploid tumors relative to diploid tumors

From: Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy

Genes Diploid tumors
(n = 24)
Aneuploid tumor
(n = 23)
pa ROC-AUCb
PLK1 1,67 (0,69-7,46) c 8,65 (2,26-35,59) 0,0000005 0,929
AURKA 4,41 (1,46-15,80) 12,92 (3,88-34,22) 0,0000006 0,924
CCNB1 2,23 (0,34-19,16) 5,56 (2,67-18,97) 0,000002 0,901
BUB1 2,96 (0,74-10,74) 6,75 (1,88-25,63) 0,00008 0,837
CDC20 1,76 (0,39-7,95) 4,70 (1,39-22,65) 0,0001 0,824
TACC3 3,81 (1,01-12,27) 8,47 (2,62-29,89) 0,0002 0,814
CDC2 4,77 (1,19-23,21) 14,39 (3,51-56,17) 0,0005 0,797
ZWINT 3,74 (1,08-14,24) 5,97 (2,61-20,70) 0,0005 0,795
BUB3 1,73 (0,74-3,63) 2,89 (1,08-10,17) 0,0007 0,789
NDC80 4,30 (1,05-23,45) 10,00 (2,96-126,38) 0,0009 0,784
TPX2 9,63 (1,65-35,79) 22,11 (5,45-117,11) 0,0009 0,783
RAD21 1,61 (0,65-5,69) 3,03 (0,78-10,73) 0,001 0,770
MAD2L2 1,20 (0,39-3,66) 1,91 (0,61-7,41) 0,002 0,767
CDC23 1,27 (0,92-2,89) 1,96 (0,95-3,96) 0,002 0,765
PPP1R2 1,94 (0,83-3,46) 2,64 (1,03-4,91) 0,004 0,733
CENPE 7,58 (0,08-39,17) 17,11 (2,88-61,89) 0,007 0,729
PTTG1 2,60 (0,01-12,91) 4,03 (2,34-9,95) 0,007 0,729
BIRC5 9,76 (1,47-43,46) 23,21 (2,32-150,30) 0,007 0,728
AURKB 3,83 (0,61-20,14) 6,62 (1,02-64,52) 0,008 0,726
CCNB2 7,74 (2,00-68,51) 17,86 (3,53-55,08) 0,01 0,714
KNTC1 1,02 (0,44-3,63) 1,75 (0,50-3,70) 0,01 0,710
TTK 4,20 (0,61-16,04) 8,05 (1,72-44,27) 0,02 0,701
CCNA2 7,62 (2,45-32,82) 13,61 (2,20-35,30) 0,02 0,692
ESPL1 2,09 (0,44-9,64) 4,59 (0,68-10,11) 0,04 0,674
CDKN1A 1,50 (0,49-3,87) 2,08 (0,76-10,29) NS 0,657
MAD2L1 1,92 (0,80-8,58) 2,34 (1,08-5,18) NS 0,647
SMC1L2 0,19 (0,00-2,15) 0,70 (0,04-10,43) NS 0,642
NEK2 18,34 (2,46-109,01) 29,31 (4,97-137,03) NS 0,638
FBXW7 0,47 (0,16-1,30) 0,61 (0,30-1,18) NS 0,631
BUB1B 6,32 (1,35-63,78) 11,35 (3,25-27,28) NS 0,626
UBD 3,47 (0,15-41,74) 4,94 (0,44-106,40) NS 0,605
CCNB3 5,90 (0,75-27,35) 6,77 (1,29-61,53) NS 0,601
CDC27 1,69 (0,74-2,46) 1,90 (0,65-5,77) NS 0,599
ANAPC4 0,86 (0,31-1,84) 0,90 (0,38-1,90) NS 0,592
MRE11A 0,72 (0,25-1,46) 0,89 (0,21-2,31) NS 0,592
ZWILCH 1,79 (0,76-4,98) 2,26 (0,98-3,50) NS 0,589
BRCA2 1,37 (0,31-7,84) 2,06 (0,69-4,87) NS 0,581
UBE2N 2,08 (1,53-3,42) 2,34 (1,58-3,42) NS 0,574
RAN 1,88 (1,05-3,33) 2,09 (1,28-15,85) NS 0,550
STAG1 0,56 (0,23-1,03) 0,58 (0,31-0,94) NS 0,549
RAE1 2,03 (1,37-4,32) 2,14 (1,15-2,88) NS 0,519
AURKC 0,77 (0,37-3,08) 0,75 (0,35-10,67) NS 0,496
AURKAIP1 2,00 (0,77-3,55) 1,83 (1,05-3,93) NS 0,466
PPP1CA 2,57 (1,23-9,80) 2,15 (1,26-11,11) NS 0,440
TACC1 1,14 (0,26-2,93) 0,99 (0,23-2,81) NS 0,430
RASSF1A 0,55 (0,10-2,13) 0,46 (0,16-1,35) NS 0,413
ANAPC7 2,32 (1,33-4,41) 2,22 (1,39-3,46) NS 0,399
PRCC 3,67 (1,94-6,62) 2,96 (1,62-6,35) NS 0,388
UBE1C 1,70 (0,67-3,71) 1,41 (0,52-2,65) NS 0,384
ANAPC2 1,05 (0,46-2,63) 0,95 (0,57-1,62) NS 0,365
FZR1 0,75 (0,29-1,49) 0,56 (0,24-1,41) 0,001 0,225
HTERT 1,00 (0,51-4,11) 1,69 (0,33-28,84) 0,04 0,678
MKI67 1,00 (0,20-4,70) 2,20 (0,72-7,41) 0,0009 0,782
ESR1 1,00 (0,29-2,78) 0,89 (0,00-3,77) NS 0,426
  1. aKruskal Wallis' H Test
  2. bROC (Receiver Operating Characteristics) - AUC (Area Under the Curve) analysis
  3. cMedian (range) gene mRNA levels. The mRNA levels of the tumor samples were normalized such that the median of the 9 normal breast tissues mRNA levels was 1.